A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer

BACKGROUND: In RAS-mutant tumors, combined MEK and autophagy inhibition using chloroquine demonstrated synthetic lethality in preclinical studies. This phase II trial evaluated the safety and activity of the MEK inhibitor binimetinib combined with hydroxychloroquine (HCQ) in patients with advanced K...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Charu, Maity, Alisha P, Bauml, Joshua M, Long, Qi, Aleman, Tomas, Ciunci, Christine, D’Avella, Christopher, Volpe, Melissa, Anderson, Evan, Jones, Lisa McCormick, Sun, Lova, Singh, Aditi P, Marmarelis, Melina E, Cohen, Roger B, Langer, Corey J, Amaravadi, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322125/
https://www.ncbi.nlm.nih.gov/pubmed/37186063
http://dx.doi.org/10.1093/oncolo/oyad106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322125/
https://www.ncbi.nlm.nih.gov/pubmed/37186063
http://dx.doi.org/10.1093/oncolo/oyad106

Ejemplares similares